论文部分内容阅读
目的探究并分析他巴唑片治疗甲状腺功能亢进的临床疗效。方法选取该院2012年1月—2013年12月收治的100例甲状腺功能亢进患者,将其作为临床研究对象,按照随机数表法将其随机分为观察组和对照组,每组各50例。其中观察组患者采取大剂量他巴唑片治疗,对照组患者采取小剂量他巴唑片治疗。观察并比较二组患者治疗后的疗效、不良反应情况,检测治疗前后的FT3、FT4、TSH水平,并进行比较。结果观察组患者治疗后总有效率为90%,明显高于对照组(68%),组间比较差异有统计学意义(P<0.05);治疗后二组患者FT3、FT4水平较治疗前明显降低,观察组治疗后FT3、FT4水平分别为(8.1±1.2)μmol/L、(18.2±4.6)μmol/L,均较对照组低,组间比较差异有统计学意义(P<0.05);二组患者治疗后TSH水平较治疗前差异无统计学意义(P>0.05),治疗后组间TSH水平比较差异无统计学意义(P>0.05);观察组患者治疗后不良反应的总发生率为32%,明显高于对照组(10%),差异具有统计学意义(P<0.05)。结论服用大剂量他巴唑治疗甲状腺功能亢进的临床疗效优于小剂量他巴唑,但大剂量他巴唑治疗后的不良反应较小剂量多,故临床上应根据患者病情选择合适剂量他巴唑治疗。
Objective To investigate and analyze the clinical efficacy of methbazole tablets in the treatment of hyperthyroidism. Methods One hundred patients with hyperthyroidism admitted from January 2012 to December 2013 in our hospital were selected as clinical research subjects and randomly divided into observation group and control group according to random number table method, . Patients in the observation group were treated with large doses of methimazole tablets, while patients in the control group were treated with lower doses of methimazole tablets. The curative effects and adverse reactions of the two groups were observed and compared. The levels of FT3, FT4 and TSH before and after treatment were detected and compared. Results The total effective rate of observation group was 90% after treatment, which was significantly higher than that of control group (68%). The difference between the two groups was statistically significant (P <0.05). After treatment, the levels of FT3 and FT4 in two groups were significantly higher than those before treatment (8.1 ± 1.2) μmol / L and (18.2 ± 4.6) μmol / L respectively in the observation group after treatment, which were lower than those in the control group (P <0.05). There was no significant difference in the level of TSH between the two groups after treatment (P> 0.05). There was no significant difference in the level of TSH between the two groups after treatment (P> 0.05). The total incidence of adverse reactions Was 32%, which was significantly higher than that of the control group (10%), the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of high-dose methimazole in the treatment of hyperthyroidism is better than that of the lower-dose methimazole, but the adverse reactions after high-dose methimazole treatment are less than that of the lower dose, so it should be clinically selected according to the patient’s condition Azole therapy.